Iovance Biotherapeutics, Inc. filings document a biotechnology company focused on polyclonal TIL therapies, including disclosures tied to Amtagvi, Proleukin, lifileucel, and broader solid-tumor cell therapy programs. Its Form 8-K reports cover operating results, financial condition, corporate presentations, clinical or regulatory disclosures, and material-event updates.
The filing record also includes proxy materials covering director elections, executive compensation, shareholder voting matters, and board governance. Capital-structure disclosures include common stock matters, registration-statement references, and material agreements related to an at-the-market offering program.
Iovance Biotherapeutics (IOVA) raised its full-year 2026 total revenue guidance to $410 million to $420 million, citing strong U.S. demand for Amtagvi and Proleukin. The midpoint increase is $55 million, or ~15%, over the previous guidance range of $350 million to $370 million; the new range implies nearly 60% annual total revenue growth.
Iovance reported record second-quarter 2026 total product revenue of $99.3 million. Its authorized treatment center (ATC) network has grown to approximately 100 centers and remains on track to reach at least 110 by year-end 2026. Management said increasing patient demand and its current manufacturing schedule provide strong visibility into third- and fourth-quarter revenue. Lifileucel continues to advance across registrational programs in new solid tumor indications, while the company cited manufacturing and operating efficiencies as accelerating progress toward profitability. Iovance describes Amtagvi as the first FDA-approved one-time treatment for previously treated advanced melanoma; it is approved in three global markets. The company expects to report third-quarter 2026 results in early November 2026.
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported that Interim CEO & General Counsel Frederick G. Vogt had 15,626 Restricted Stock Units (RSUs) vest on September 8, 2026, converting into an equal number of common shares. Of these, 6,638 shares were withheld by the company to satisfy mandatory tax withholding obligations, which the disclosure states is not an open market sale. Following this RSU vesting event, Vogt continues to hold 93,756 RSUs from the March 5, 2025 grant, which are scheduled to vest in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported that Chief Operating Officer Igor Bilinsky had restricted stock units vest on September 8, 2026, resulting in the acquisition of 7,813 shares of common stock. These shares came from RSUs converting into common stock at no cash exercise price, with each RSU representing one share. Of the vested shares, 3,976 shares of common stock were withheld by the company at a price of $8.70 per share to satisfy mandatory tax withholding obligations, and this was explicitly stated not to be an open market sale. After this vesting event, 46,878 RSUs from the March 5, 2025 grant remain outstanding and will vest in equal quarterly installments, and no transactions were reported as made under a Rule 10b5-1 trading plan.
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported that Chief Regulatory Officer Raj K. Puri had restricted stock units vest on September 8, 2026, converting 9,766 RSUs into an equal number of common shares. Of these, 4,478 shares were withheld by the company at $8.70 per share to satisfy mandatory tax withholding requirements, which the company notes was not an open-market sale. Following the RSU exercise, 58,599 RSUs from the March 5, 2025 grant remain outstanding and will vest in equal quarterly installments, and no Rule 10b5-1 trading plan is reported.
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported that Interim CEO & General Counsel Frederick G. Vogt had 41,669 restricted stock units (RSUs) vest on September 1, 2026, resulting in the acquisition of an equal number of common shares. Of these, 17,702 shares were withheld by the company at $8.28 per share to satisfy mandatory tax withholding, which the disclosure states was not an open market sale. Following the vesting, 83,338 RSUs from the March 1, 2024 grant remain unvested, in addition to other RSUs he holds.
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported that Chief Regulatory Officer Raj K. Puri had 5,470 Restricted Stock Units (RSUs) vest on September 1, 2026, each converting into one share of common stock. Of these, 2,508 shares of common stock were withheld by the company at $8.28 per share to satisfy mandatory tax withholding requirements, which is explicitly stated not to be an open market sale. Following this vesting event, 10,939 RSUs remain outstanding from the March 1, 2024 grant, in addition to any other RSUs he holds under separate awards.
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported that Chief Operating Officer Igor Bilinsky had 8,789 Restricted Stock Units (RSUs) vest on September 1, 2026, resulting in the issuance of 8,789 shares of common stock. Of these, 4,472 shares of common stock were withheld at $8.28 per share to satisfy mandatory tax withholding, which the company states was not an open market sale. Following the transaction, 17,580 RSUs from the March 1, 2024 grant remain outstanding and will vest in equal quarterly installments; this aggregate RSU figure does not include any other RSUs he holds.
IOVANCE BIOTHERAPEUTICS, INC. reported that Chief Commercial Officer Kirby Daniel Gordon had 10,001 Restricted Stock Units vest and convert into an equal number of common shares on August 10, 2026. Of these, 2,436 shares were delivered or withheld at $6.40 per share to satisfy mandatory tax withholding, which was not an open-market sale. Following the vesting, Gordon held 60,003 RSUs from the February 10, 2025 grant, with the remaining units scheduled to vest in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS, INC. Chief Financial Officer Corleen M. Roche reported the vesting of 49,995 Restricted Stock Units on August 6, 2026, converting into an equal number of common shares. Of these, 21,238 shares were withheld at $6.21 per share to satisfy mandatory tax withholding, leaving 28,757 shares of common stock from this vesting. Following the transaction, she continues to hold 100,005 RSUs from the August 6, 2025 grant, separate from any other RSUs she holds.
State Street Corporation reported beneficial ownership of common stock of Iovance Biotherapeutics, Inc. This filing states that State Street and certain investment adviser subsidiaries collectively beneficially own 24,478,268 shares of Iovance common stock, representing 5.5% of the class.
The group reports 0 shares with sole voting or dispositive power, and 23,483,868 shares with shared voting power and 24,478,268 shares with shared dispositive power. Subsidiaries listed include SSGA Funds Management, Inc. and several State Street Global Advisors entities.